Is Amazon an AI Stock?
With the market starting to look skittish on pure-play AI…
Sell
48
ORIC Quote, Financials, Valuation and Earnings
Last price:
$11.37
Seasonality move
:
1.47%
Day range:
$10.72 - $11.54
52-week range:
$3.90 - $14.93
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
2.73x
Volume:
1.3M
Avg. volume:
1.2M
1-year change:
16.22%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$1.73
Analysts' Opinion
-
Consensus RatingOric Pharmaceuticals, Inc. has received a consensus rating of Buy. The company's average rating is a Buy based on 12 Buy ratings, 1 Hold rating, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $19.92, Oric Pharmaceuticals, Inc. has an estimated upside of 74.86% from its current price of $11.39.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $15.00 representing -31.69% downside risk from its current price of $11.39.
Fair Value
-
According to the consensus of 13 analysts, Oric Pharmaceuticals, Inc. has 74.86% upside to fair value with a price target of $19.92 per share.
ORIC vs. S&P 500
-
Over the past 5 trading days, Oric Pharmaceuticals, Inc. has underperformed the S&P 500 by -3.75% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
Oric Pharmaceuticals, Inc. does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Oric Pharmaceuticals, Inc. has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Oric Pharmaceuticals, Inc. reported revenues of --.
Earnings Growth
-
Oric Pharmaceuticals, Inc. has grown year-over-year earnings for 1 quarter straight. In the most recent quarter Oric Pharmaceuticals, Inc. reported earnings per share of -$0.33.
Enterprise value:
825.4M
EV / Invested capital:
2.01x
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
-0.88x
EV / Free cash flow:
-6.90x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
-$1.2M
Return On Assets:
-42.28%
Net Income Margin (TTM):
--
Return On Equity:
-46.08%
Return On Invested Capital:
-45.39%
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -$1M | -$1.1M | -$1.2M | -$270K | -$288K | |
| Operating Income | -$101.5M | -$134.8M | -$148M | -$38.3M | -$36.7M | |
| EBITDA | -$100.5M | -$133.7M | -$146.8M | -$38M | -$36.4M | |
| Diluted EPS | -$2.00 | -$1.81 | -$1.73 | -$0.49 | -$0.33 | |
| Period Ending | 2021-09-30 | 2022-09-30 | 2023-09-30 | 2024-09-30 | 2025-09-30 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $292.8M | $198.7M | $232.2M | $279.4M | $295.6M | |
| Total Assets | $314.2M | $238M | $274.3M | $302.1M | $431.2M | |
| Current Liabilities | $11.9M | $13.3M | $18.9M | $21.2M | $20.2M | |
| Total Liabilities | $22.6M | $23.2M | $26.9M | $28.1M | $24.3M | |
| Total Equity | $291.5M | $214.8M | $247.4M | $274M | $406.9M | |
| Total Debt | $1.8M | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-09-30 | 2024-09-30 | 2025-09-30 | 2024-09-30 | 2025-09-30 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$77.1M | -$109.3M | -$118.9M | -$28.8M | -$26.9M | |
| Cash From Investing | -$36.1M | $445K | -$122.4M | $23.1M | -$110.5M | |
| Cash From Financing | $110.4M | $126.8M | $246.7M | $126K | $111.2M | |
| Free Cash Flow | -$78.2M | -$110.3M | -$119.6M | -$29.2M | -$26.9M | |
ORIC
Sector
Market Cap
$1.1B
$28.4M
Price % of 52-Week High
76.29%
50.35%
Dividend Yield
0%
0%
Shareholder Yield
-21.15%
-1.32%
1-Year Price Total Return
16.23%
-22.19%
Beta (5-Year)
1.324
0.521
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$11.41
200-day SMA
Buy
Level
$9.37
Bollinger Bands (100)
Sell
Level
10.12 - 12.7
Chaikin Money Flow
Buy
Level
2.4M
20-day SMA
Sell
Level
$11.85
Relative Strength Index (RSI14)
Sell
Level
43.98
ADX Line
Sell
Level
11.1
Williams %R
Neutral
Level
-68.5524
50-day SMA
Sell
Level
$12.41
MACD (12, 26)
Sell
Level
-0.35
25-day Aroon Oscillator
Sell
Level
-84
On Balance Volume
Neutral
Level
59M
Financial Scores
Buy
Altman Z-Score
(Annual)
Level (6.7109)
Sell
CA Score
(Annual)
Level (-1.1494)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (9)
Sell
Ohlson Score
Level (5.6143)
--
Piotroski F Score
(Annual)
Level (--)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (2)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Oric Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in the development of cancer treatments that address mechanisms of therapeutic resistance. It specializes in hormone-dependent cancers, key tumor dependencies, and precision oncology. The company was founded by Charles L. Sawyers, Richard A. Heyman, and Scott Lowe in 2014 and is headquartered in South San Francisco, CA.
Stock Forecast FAQ
In the current month, ORIC has received 12 Buy ratings 1 Hold ratings, and 0 Sell ratings. The ORIC average analyst price target in the past 3 months is $19.92.
-
Where Will Oric Pharmaceuticals, Inc. Stock Be In 1 Year?
According to analysts, the consensus estimate is that Oric Pharmaceuticals, Inc. share price will rise to $19.92 per share over the next 12 months.
-
What Do Analysts Say About Oric Pharmaceuticals, Inc.?
Analysts are divided on their view about Oric Pharmaceuticals, Inc. share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Oric Pharmaceuticals, Inc. is a Sell and believe this share price will drop from its current level to $15.00.
-
What Is Oric Pharmaceuticals, Inc.'s Price Target?
The price target for Oric Pharmaceuticals, Inc. over the next 1-year time period is forecast to be $19.92 according to 13 Wall Street analysts, 12 of them rate the stock a Buy, 0 rate the stock a Sell, and 1 analyst rates the stock a Hold.
-
Is ORIC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Oric Pharmaceuticals, Inc. is a Buy. 12 of 13 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of ORIC?
You can purchase shares of Oric Pharmaceuticals, Inc. via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Oric Pharmaceuticals, Inc. shares.
-
What Is The Oric Pharmaceuticals, Inc. Share Price Today?
Oric Pharmaceuticals, Inc. was last trading at $11.37 per share. This represents the most recent stock quote for Oric Pharmaceuticals, Inc.. Yesterday, Oric Pharmaceuticals, Inc. closed at $11.39 per share.
-
How To Buy Oric Pharmaceuticals, Inc. Stock Online?
In order to purchase Oric Pharmaceuticals, Inc. stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
Get ORIC Stock Alert
Signup to receive the latest stock alerts
Financial Ratios
ORIC
Sector
P/E ratio
--
23.66x
PEG ratio
-0.88x
-0.01x
P/B ratio
2.73x
1.84x
Price / LTM sales
--
1.60x
Growth Metrics
ORIC
Sector
Revenue growth
--
4.85%
Earnings growth
32.8%
11.15%
Revenue (5-year growth)
--
6.45%
Earnings forecast
-$0.40
-$0.20
Profitability
ORIC
Sector
Profitability FY 2024
-$1.1M
$3.6M
Return on invested capital
-45.39%
-30.98%
Return on assets
-42.28%
-27.62%
Return on equity
-46.08%
-36.69%
Earnings Date
Last Earnings Date
Nov
13
Next Earnings Date
Feb
17
Estimated Next Earnings Date
Feb
12
Balance Sheet
ORIC
Sector
Total cash
$287.1M
$27.2M
Short term investments
$196.6M
$25.7M
Total assets
$276.7M
$79.9M
Long term debt
--
$4.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Google Vs NVIDIA Stock: Which Is Best?
Alphabet (NASDAQ:GOOGL) and NVIDIA (NASDAQ:NVIDIA) are two of the market’s…
How High Could NVIDIA Stock Go?
NVIDIA (NASDAQ:NVDA) has been one of the best stocks to…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 62x
Buy
61
Is AAPL Stock a Buy?
Market Cap: $4.1T
P/E Ratio: 38x
Buy
63
Is GOOG Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 40x
Alerts
Buy
54
SMX alert for Dec 5
SMX (Security Matters) Plc [SMX] is up 154.74% over the past day.
Sell
15
HOV alert for Dec 5
Hovnanian Enterprises, Inc. [HOV] is down 22.58% over the past day.
Buy
67
NUTX alert for Dec 5
Nutex Health, Inc. [NUTX] is up 18.9% over the past day.
THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS
Show me the best stock
